Intra-Cellular Therapies, Inc.
ITCI
Hisse Senetlerindeki Sıralama
#1683
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Hisse Fiyatı
$131.87
Son senkronizasyon: 2025-04-02
Piyasa Değeri
$12.68B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Intra-Cellular Therapies, Inc. (ITCI) için kazanç
Dec 2024 itibarıyla kazanç TTM: $-74.20M
Intra-Cellular Therapies, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-74.20M'dir. 2023 yılında şirket $-139.04M kazanç elde etti, bu 2022 yılındaki $-256.25M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Intra-Cellular Therapies, Inc. için kazanç geçmişi 2013 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-74.20M | 0.00% |
| 2024 | $-74.20M | -46.63% |
| 2023 | $-139.04M | -45.74% |
| 2022 | $-256.25M | -9.81% |
| 2021 | $-284.12M | 25.17% |
| 2020 | $-226.99M | 53.66% |
| 2019 | $-147.72M | -4.77% |
| 2018 | $-155.13M | 56.96% |
| 2017 | $-98.83M | -14.33% |
| 2016 | $-115.36M | 10.09% |
| 2015 | $-104.79M | 241.45% |
| 2014 | $-30.69M | 14.30% |
| 2013 | $-26.85M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -2,478.01% |
IN
|
